Neumora Therapeutics (NMRA) Retained Earnings (2022 - 2026)
Neumora Therapeutics' quarterly Retained Earnings came in at -$1.2 billion in Q1 2026, down 21.91% year-on-year from -$1.6 billion in Q1 2025, and down 4.51% quarter-over-quarter from -$1.2 billion in Q4 2025.
Neumora Therapeutics has reported Retained Earnings for 5 years, with the latest figure at -$1.2 billion in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 21.91% year-over-year to -$1.2 billion; the trailing twelve-month figure through Mar 2026 stood at -$1.2 billion (down 21.91% YoY), and the FY2025 full-year result was -$1.2 billion, down 25.01% from the prior year.
- Retained Earnings for Q1 2026 stood at -$1.2 billion, down from -$1.2 billion in the prior quarter.
- The five-year high for Retained Earnings was -$311000.0 in Q3 2023, with the low at -$1.2 billion in Q1 2026.
- Average Retained Earnings over 5 years is -$811.9 million, with a median of -$917.8 million recorded in 2024.
- Year-over-year, Retained Earnings slumped 285559.81% in 2024 and decreased 21.91% in 2026.
- Tracing NMRA's Retained Earnings over 5 years: stood at -$774000.0 in 2022, then plunged by 90782.95% to -$703.4 million in 2023, then sank by 34.66% to -$947.2 million in 2024, then declined by 25.01% to -$1.2 billion in 2025, then fell by 4.51% to -$1.2 billion in 2026.
- The last three Retained Earnings figures came in at -$1.2 billion (Q1 2026), -$1.2 billion (Q4 2025), and -$1.1 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Neumora Therapeutics | 328.27 Mn | 328.27 Mn | - | -1.24 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.24 Bn |
| Dec 31, 2025 | -1.18 Bn |
| Sep 30, 2025 | -1.12 Bn |
| Jun 30, 2025 | -1.07 Bn |
| Mar 31, 2025 | -1.02 Bn |
| Dec 31, 2024 | -947.22 Mn |
| Sep 30, 2024 | -888.40 Mn |
| Jun 30, 2024 | -815.86 Mn |
| Mar 31, 2024 | -757.16 Mn |
| Dec 31, 2023 | -703.43 Mn |
| Sep 30, 2023 | -311,000.00 |
| Dec 31, 2022 | -774,000.00 |